Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Alexion Pharm Inc 121 SEAPORT BOULEVARD BOSTON MA 02210 USA

P: 475-230-2596 F: 203-271-8198

Description:

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

Key Statistics

Overview:

Market Capitalization, $K 25,014,216
Shares Outstanding, K 219,173
Annual Sales, $ 4,991 M
Annual Net Income, $ 2,404 M
Last Quarter Sales, $ 1,445 M
Last Quarter Net Income, $ -1,068,100 K
60-Month Beta 1.39
% of Insider Shareholders 4.03%
% of Institutional Shareholders 90.12%
Float, K 210,340
% Float 95.97%

Growth:

1-Year Return 7.36%
3-Year Return -20.09%
5-Year Return -23.53%
5-Year Revenue Growth 123.44%
5-Year Earnings Growth 109.91%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 3.11 on 07/30/20
Next Earnings Date 10/28/20
Earnings Per Share ttm 10.95
EPS Growth vs. Prev Qtr -4.97%
EPS Growth vs. Prev Year 16.67%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 2-1 on 05/23/11

ALXN Ratios

Ratio
Price/Earnings ttm 10.65
Price/Earnings forward 21.19
Price/Earnings to Growth 0.85
Return-on-Equity % 22.57%
Return-on-Assets % 14.73%
Profit Margin % 48.17
Net Margin % 17.85
Debt/Equity 0.20
Price/Sales 5.12
Price/Cash Flow 9.98
Price/Book 2.41
Book Value/Share 47.87
Interest Coverage 29.01
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar